Quick Answer
Vir Biotechnology, Inc. reported R&D Expense of $455.97 million for fiscal year 2025.
Vir Biotechnology, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $455.97M | -10.0% |
| 2024 | $506.50M | -12.6% |
| 2023 | $579.72M | +22.1% |
| 2022 | $474.65M | +5.9% |
| 2021 | $448.01M | +48.1% |
| 2020 | $302.41M | +103.7% |
| 2019 | $148.47M | +48.1% |
| 2018 | $100.23M | +60.3% |
| 2017 | $62.51M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $151.46M | -22.4% | +55.3% |
| June 30, 2025 | $97.51M | -7.2% | -17.8% |
| March 31, 2025 | $118.64M | +18.5% | -39.2% |
| September 30, 2024 | $195.18M | +34.6% | +85.7% |
| June 30, 2024 | $105.11M | -37.5% | +5.0% |
| March 31, 2024 | $100.12M | -36.5% | -31.0% |
| September 30, 2023 | $145.03M | +27.0% | -13.7% |
| June 30, 2023 | $168.08M | +46.1% | +6.6% |
- Vir Biotechnology, Inc. showed a decrease of -10.0% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Vir Biotechnology, Inc.’s r&d expense has grown by 629.4% (from $62.51 million to $455.97 million).
- The most recent figure is from Vir Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: